Acceleron Pharma (XLRN) Tops Q3 EPS by 10c

Acceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.36), $0.10 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $4.16 million versus the consensus estimate of $4.38 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Stanley Black & Decker agrees to sell Hustler mower unit to Bad Boy Mowers
• SoundHound AI completes LivePerson acquisition, names new CFO